PCI Announces Expansion of Packaging Capacity
News Mar 14, 2014
Packaging Coordinators, Inc. (PCI) has announced the completion of the planned expansion of its packaging facilities in Rockford, IL.
The Rockford site is one of three locations in the United States, and the facilities expansion in Rockford was designed to accommodate continued business development in its contract packaging services.
PCI converted underutilized space to further support its expanding packaging operations, adding 20,000 square feet for secondary and tertiary packaging. The additional production capacity will enable continued growth in operations such as cartoning, overwrapping, heat seal carding and compliance prompting packaging, as well as supporting packaging for biotech delivery forms such as secondary packaging for injectable vials, syringes, devices, and transdermal products. The packaging operations support both commercial operations as well as large-scale clinical studies.
In addition to packaging of commercial medicines, PCI provides clinical packaging services for investigational medicines at the Rockford location supported by on-site Storage and Distribution Services, facilitating global logistics for clinical studies.
In December 2013 PCI has announced the groundbreaking of a new 93,000 square foot Storage and Distribution site for investigational medicines, currently slated to be in operation in August of this year.
The clinical services expansion complements investments in PCI’s UK operations, most recently construction of a Storage and Distribution facility near Cardiff, Wales.
“The facilities expansion we have undertaken in Rockford is the latest in a series of investments we have made to enable continued growth and at the same time continue to provide our customers the extraordinary service they have come to expect from PCI,” states Bill Mitchell, President and Chief Executive Officer at PCI. “We are committed to providing an unparalleled customer experience with our clinical and commercial services, and those services require world class facilities. We are very excited about what these investments bring to our expanding business and our ability to support our clients.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018